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ABSTRACT
Objective Pancreatic ductal adenocarcinoma (PDA) is
characterised by stromal desmoplasia and vascular
dysfunction, which critically impair drug delivery. This
study examines the role of an abundant extracellular
matrix component, the megadalton glycosaminoglycan
hyaluronan (HA), as a novel therapeutic target in PDA.
Methods Using a genetically engineered mouse model of
PDA, the authors enzymatically depleted HA by a clinically
formulated PEGylated human recombinant PH20
hyaluronidase (PEGPH20) and examined tumour perfusion,
vascular permeability and drug delivery. The preclinical
utility of PEGPH20 in combination with gemcitabine was
assessed by short-term and survival studies.
Results PEGPH20 rapidly and sustainably depleted HA,
inducing the re-expansion of PDA blood vessels and
increasing the intratumoral delivery of two
chemotherapeutic agents, doxorubicin and gemcitabine.
Moreover, PEGPH20 triggered fenestrations and
interendothelial junctional gaps in PDA tumour endothelia
and promoted a tumour-specific increase in
macromolecular permeability. Finally, combination therapy
with PEGPH20 and gemcitabine led to inhibition of PDA
tumour growth and prolonged survival over gemcitabine
monotherapy, suggesting immediate clinical utility.
Conclusions The authors demonstrate that HA impedes
the intratumoral vasculature in PDA and propose that its
enzymatic depletion be explored as a means to improve
drug delivery and response in patients with pancreatic
cancer.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is a malig-
nancy with a dire prognosis due to aggressive disease
on clinical presentation and poor chemotherapeutic
response.1 The fluorinated nucleoside analogue
gemcitabine (29,29-difluorodeoxycytidine, dFdC)
remains the antineoplastic agent of choice, offering
a survival benefit of little more than 5 weeks,2 while
gemcitabine-based combination therapies have
shown limited progress in advancing survival.3
Understanding of genetic alterations in PDA has
allowed the generation of genetically engineered
mouse models (GEMMs), bearing autochthonous
tumours that recapitulate the human pathology.4e6
A mechanism for intrinsic gemcitabine resistance
has recently been reported in one such GEMM, the
LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC)
mouse.7 Compared with subcutaneous tumours of
syngeneic origin, KPC tumours demonstrated
a desmoplastic stroma and lower mean vessel
densities, thus limiting the accumulation of the
active gemcitabine triphosphate (dFdCTP).7 A
similar perfusion deficit has been observed in an
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Significance of this study
What is already known on this subject?
< The tumour microenvironment in PDA is
characterised by hypovascularity and extensive
deposits of extracellular matrix components.
< The desmoplastic and hypovascular nature of
PDA contributes to its unique therapeutic resis-
tance in part by impairing efficient drug delivery.
What are the new findings?
< HA is a non-sulphated glycosaminoglycan that is
highly abundant in the extracellular matrix of
human and murine PDA.
< Enzymatic depletion of HA by PEGPH20 induced
the re-expansion of PDA blood vessels and
increased the delivery of two chemotherapeutic
agents in a genetically engineered mouse model
of PDA.
< PEGPH20 promoted a tumour-specific increase
in macromolecular permeability and induced
fenestrations and interendothelial junctional
gaps in PDA endothelia.
< Combination therapy with PEGPH20 and gemci-
tabine inhibits tumour growth and prolongs
survival in a genetically engineered mouse
model of PDA.
How might it impact on clinical practice in the
foreseeable future?
< Increasing drug delivery to hypovascular and
stroma-rich tumours is a promising strategy to
circumvent therapeutic resistance in PDA. HA is
an attractive target in the tumour microenviron-
ment of PDA.
< The synergism of PEGPH20 and gemcitabine is
of immediate clinical significance and provides
support for investigational trials with this
therapeutic combination.
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independent study in mice and human PDA.8 9 Stromal deple-
tion by Smoothened inhibition in KPC mice increased perfusion,
intratumoral dFdCTP and overall survival, suggesting that
therapeutic failure of gemcitabine arises from a potentially
reversible impairment in drug delivery.7
Of note, the scarcity of tumour vessels is compounded by
a vessel perfusion mismatch,7 8 which is likely a result of
interstitial hypertension and vascular compression.10e12
Vascular hyperpermeability, water retention by extracellular
matrix components and inadequate lymphatic drainage
contribute towards interstitial fluid pressure (IFP) in solid
tumours, and its selective decrease in malignant tissues repre-
sents an approach in maximising the delivery and hence the
therapeutic indices of chemotherapeutic agents.13 Indeed, the
IFP reduction associated with vascular endothelial growth factor
(VEGF) inhibitors is likely central to their clinically beneficial
synergism with cytotoxic agents.14
Hyaluronan (HA) is a non-sulphated glycosaminoglycan
present in the extracellular matrix, composed of N-acetylglu-
cosamine/glucuronic acid disaccharide repeats of variable length.
HA may signal through ‘hyaladherins’ such as CD44 to regulate
receptor tyrosine kinase and small GTPase activity and is
implicated in the processes of angiogenesis, epitheliale
mesenchymal transition and chemoresistance.15 Moreover, HA’s
anionic repeats also sequester mobile cations and solvating
water, resulting in osmotic swelling that provides structural
support in HA-rich normal and malignant tissues.16 Degradation
of HA by intratumoral administration of bovine hyaluronidases
showed promise in diminishing tumorous IFP and increasing
chemotherapeutic index in xenograft models,17 18 but systemic
administration was limited by short residence time and immu-
nogenicity.19 PEGPH20, a PEGylated human recombinant PH20
hyaluronidase, surmounts these issues and has demonstrated
comparable activity in vivo, inducing rapid perfusion increase in
xenograft tumours.20
HA is a known secretory product of several human pancreatic
carcinoma cell lines21 and has been shown as an over-represented
glycosaminoglycan in human PDA,22 localised to the stroma and
peritumoral connective tissue.23 However, in contrast to other
epithelial cancers, the pathological significance of its rheological
and signalling properties has not been fully investigated in this
malignancy.24 In this study, we sought to investigate the aeti-
ology of vascular compression in the KPC GEMM and identified
HA as a critical modifier of tumorous vascular function. Its
enzymatic depletion by PEGPH20 resulted in an improvement in
tumour vascular patency, as well as an unexpected selective
change in tumour endothelial ultrastructure and macromolecular
permeability. Our data predict hyaluronidase synergism with
cytotoxic agents and demonstrate a significant survival benefit
with combination therapy, providing HA as a novel stromal
therapeutic target to consider for patients with pancreatic cancer.
MATERIALS AND METHODS
Mice
Experiments were carried out within the Cancer Research UK
Cambridge Research Institute’s Biological Resources Unit, under
the terms of the Home Office Project Licenses PPL80/2072 and
80/2539 and subject to Cancer Research UK ethical review. The
generation of tumour-bearing KPC (LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx-1-Cre) mice has previously been described.5
Where appropriate, PC (LSL-Trp53R172H/+;Pdx-1-Cre) littermates,
which did not develop any pancreatic lesions within the exper-
imental time frame, served as healthy controls. KPC mice were
enrolled onto studies once tumour volume reached 2706100 mm3,
as assessed by three-dimensional ultrasonography.7
Vascular function studies
At least four mice were evaluated for each experimental arm. One
hour after the final dose of PEGPH20, mice received an intrave-
nous infusion of fluorophore-labelled lectin only (vascular
patency assay) or of fluorophore-labelled lectin and dextrans
(permeability assay). Thirty minutes later, mice were terminally
perfused with 30 ml of 4% paraformaldehyde/phosphate buffered
saline (pH 7.4). Perfused tissues were harvested, fixed for 16e24 h
in paraformaldehyde and transferred to 70% ethanol before
paraffin embedding. Sections were deparaffinised, rehydrated and,
for vascular patency assays, immunostained for MECA-32 (see
Immunostaining and HA histochemistry section). All sections
were counterstained with 49,6-diamidino-2-phenylindole (DAPI).
Visualisation was performed on a Leica SP5 confocal microscope
(Leica Microsystems, Wetzlar, Germany) using standardised
settings, and background signal intensities were established
against unlabelled terminally perfused samples. Mean vessel
densities were quantified as the average number of CD31+ vessels
in a minimum of 10 non-adjacent 403 fields.
Pharmacodelivery studies
For the doxorubicin delivery assay, a minimum of five mice from
each arm were included for analysis. Mice received an intrave-
nous infusion of doxorubicin 1 h after the final dose of
PEGPH20. Mice were then terminally perfused with para-
formaldehyde, and tissues processed as above. Sections were
deparaffinised, rehydrated and counterstained with DAPI.
Doxorubicin fluorescence was quantified with the CompuCyte
iCys Research Imaging Cytometer and iNovator software
(CompuCyte Westwood, MA, USA), as previously described.7
Table 1 Human TMA
Tissue origin % Cases with +HA staining
Breast Tumour (N¼117, 56%)
Normal (N¼13, 23%)
Prostate Tumour (N¼110, 46%)
Normal (N¼17, 5.8%)
Bladder Tumour (TCC) (N¼106, 43%)
Normal (N¼8, 0%)
Stomach Tumour (adenocarcinoma) (N¼95, 42%)
Normal (N¼14, 0%)
Pleura Tumour (mesothelioma) (N¼52, 37%)
Normal (N¼15, 0%)
Lung NSCLC (N¼169, 29%)
SCLC (N¼21, 10%)
Normal (N¼21, 0%)
Ovary Tumour (N¼185, 12%)
Normal (N¼31, 0%)
Colon Tumour (N¼136, 28%)
Normal (N¼25, 8%)
Bone marrow Multiple myeloma (N¼27, 3.7%)
Normal (N¼35, 0%)
Pancreas Ductal adenocarcinoma (N¼99, 90%)
Acinar cell carcinoma (N¼2, 0%)
Mucinous adenocarcinoma (N¼5, 100%)
Papillary adenocarcinoma (N¼4, 25%)
Squamous cell carcinoma (N¼2, 100%)
Normal (N¼25, 4%)
HA staining is most common in pancreatic ductal adenocarcinoma in
comparison to other major human tumours.
HA, hyaluronan. TMA, tissue microarray. TCC, transitional cell
carcinoma. NSCLC, non-small cell lung carcinoma. SCLC, small cell lung
carcinoma.
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For the gemcitabine delivery assay, a minimum of five mice
from each arm were included for analysis. Mice received intra-
venous gemcitabine 8 h after a single dose of PEGPH20 or
vehicle. Plasma was obtained by cardiac puncture under terminal
isoflurane anaesthesia, 2 h after gemcitabine administration, and
tissues were harvested shortly thereafter. All samples were
frozen in liquid nitrogen and processed as described for liquid
chromatography-tandem mass spectrometry analysis of fluori-
nated metabolites.25
Survival study
KPC mice bearing tumours of 2706100 mm3 were assigned to
one of four armsdvehicle, intraperitoneal gemcitabine, PEGPH20
or PEGPH20/intraperitoneal gemcitabine in combination (dosed
30 min apart)dand treatments were administered accordingly.
Once enrolled onto a survival study, mice were monitored by
three-dimensional ultrasonography every 3 days to allow calcu-
lation of tumour volumes. Endpoint criteria were defined as 20%
body weight loss in addition to general morbidity, lethargy, lack of
social interaction or development of ascites.
Immunostaining and HA histochemistry
Samples at study end point were fixed in 4% paraformaldehyde
or in 10% neutral buffered formalin for 16e24 h and transferred
to 70% ethanol before paraffin embedding. Three-micrometre
sections were generated, and one section from each sample was
stained with H&E for analysis of morphological integrity. Where
appropriate, stained sections were scanned at 203magnification
using Aperio ScanScope CS instrument and were analysed in
Spectrum (Aperio Vista, CA, USA).
For immunostaining with most antibodies, sections were
deparaffinised, rehydrated and antigen retrieval performed with
citric acid (pH 6.0) in an 850 W microwave. For CD31 immu-
nostaining, antigen retrieval was performed with proteinase K at
378C. Non-specific protein binding was blocked with 10% goat
serum (Sigma St Louis, MA, USA) for immunohistochemistry and
10% donkey serum (Sigma) for immunofluorescence. Sections
were incubated with primary antibodies for 1 h at room temper-
ature or overnight at 48C. The primary antibodies used were
against PV-1 (MECA-32, 1:50; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and CD31 (MEC 13.3, 1:50; BD Biosciences,
Franklin Lakes, NJ, USA). For immunohistochemistry, remaining
steps were carried out using appropriate Vectastain Elite ABC kits
(Vector Laboratories, Burlingame, CA, USA) and DAB Peroxidase
Substrate (Vector Laboratories), with haematoxylin counter-
staining. For immunofluorescence, sections were incubated with
appropriate AlexaFluor-conjugated secondary antibodies for 1 h at
room temperature and counterstained with DAPI.
For HA histochemistry, biotinylated HA binding protein
(bHABP, Calbiochem catalogue number 385911; Merck KGaA,
Darmstadt, Germany) was used. Sections were deparaffinised,
rehydrated and blocked with 3% bovine serum albumin (BSA)
Figure 1 Hyaluronan (HA)
accumulates in pancreatic ductal
adenocarcinoma (PDA) and may be
rapidly and sustainably degraded by
PEGPH20. (A) HA expression in human
pancreatic cancer samples (ieiii) varies
from low expression (HA1+) to high
expression (HA3+), with little HA
detected in normal pancreas (top left
panel) (scale bar: inset 300 mm,
100 mm). (B) HA expression in normal
pancreas and PDA over time after
treatment with PEGPH20. PEGPH20
treatment specifically degrades HA in
normal pancreas (top row) 1 h after
treatment. Maximal HA degradation
was achieved in KPC tumours 8 h after
PEGPH20 treatment that still remained
low even 72 h after treatment. n¼3
mice per time point (scale bar:
200 mm).
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prior to incubation with bHABP (1:200 in 1% BSA) overnight at
48C. Remaining steps were carried out using Vectastain Elite ABC
kit Standard (Vector Laboratories) and DAB Peroxidase Substrate
(Vector Laboratories), with haematoxylin counterstaining.
HA tissue microarray
Tissue microarrays were purchased from US Biomax Inc Rockville,
MD, USA and stained with bHABP as described above. The slides
were scanned at 203 magnification using Aperio ScanScope CS
instrument and analysed in Spectrum automated slide analysis
software (Aperio) using the positive pixel count algorithm. A ratio
of strong positive stain area to the sum of total stained area was
calculated and scored as 3+, 2+, 1+ or 0 when the ratio was more
than 25%, 10%e25%, less than 10% or 0, respectively. See
Supplemental Methods for further information.
Statistical analysis
GraphPad Prism 5 was used for all statistical analyses. The log-
rank test was performed on the KaplaneMeier survival curves,
and the ManneWhitney U test was performed for all other
analyses.
RESULTS
HA accumulates in PDA and may be rapidly and sustainably
degraded by PEGPH20
Using a modified histochemical method with bHABP and
computer-assisted analysis, we examined the HA content in 204
normal and 1130 malignant human tissue samples. While
a minority of normal epithelia demonstrated 1+ staining, HA
was more frequently and abundantly detected in epithelial
malignancies (table 1). Human PDA had the highest incidence of
detectable HA content, and the majority of PDA samples was
scored 2+ (figure 1A and data not shown). Notably, HA staining
was predominantly associated with the desmoplastic stroma
rather than with tumour cells. These histopathological observa-
tions were recapitulated in the tumours of KPC mice, where 2+
HA staining was observed in the stroma of most ductal
tumours (figure 1B). This confirmed the suitability of the
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Figure 2 Depletion of hyaluronan improves vascular patency and increases chemotherapeutic delivery. (A) Fluorescence images of KPC tumours
from vehicle-treated (top row, V) and PEGPH20-treated (bottom row, P) mice (n¼4 animals in each cohort) terminally perfused with fluorescent
biotinylated lectin (red). Total blood vessels are detected with MECA-32 antibody (green). White arrows denote functional vessels (red and green).
Yellow arrows denote non-functional vessels (green only). Quantification of vessel patency indicates a significant increase in functional vessels after
treatment with PEGPH20 (n¼4 mice in each cohort, >100 vessels per mouse). Scale bar ¼ 100 mm. ManneWhitney U test, *p¼0.0286. (B)
Quantification of mean vessel area (in square micrometres) from anti-CD31-stained KPC tumours from vehicle-treated (V) or PEGPH20-treated (P) mice.
A significant increase in mean vessel area is observed after treatment with PEGPH20, ManneWhitney U test, **p¼0.0085. (C) Fluorescent image of
representative KPC tumour from vehicle-treated (top panel) and PEGPH20-treated (bottom panel) mice terminally perfused with autofluorescent small-
molecule doxorubicin (pseudo-coloured green, n¼4 mice in each cohort). Scale bar ¼ 1 mm. Dotted white line denotes border between tumour core
and adjacent diseased pancreatic tissue. Quantification of intratumoral doxorubicin as measured by fluorescence ratio in vehicle-treated (V) and
PEGPH20-treated (P) KPC mice pancreatic ductal adenocarcinoma. Significant increase in intratumoral doxorubicin in PEGPH20-treated samples,
ManneWhitney U test, *p¼0.0260. (D) Quantification of intratumoral gemcitabine triphosphate (dFdCTP), the active metabolite of gemcitabine (G),
from vehicle- and PEGPH20-pretreated KPC mice. Significant increase in dFdCTP in PEGPH20-treated tumours, ManneWhitney U test, **p¼0.0053.
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Figure 3 Depletion of hyaluronan increases macromolecular permeability and induces ultrastructural changes in tumour endothelia. (A) Representative
fluorescent images of KPC tumour from vehicle-treated (top panel) and PEGPH20-treated (bottom panel) mice (n¼4 mice for each cohort). Mice
terminally treated with either low (40 kDa) or high (2 MDa) molecular weight dextrans with biotinylated lectin demonstrate a considerable increase in
stromal and vessel permeability at the tumour core in PEGPH20-treated tumours. Arrows denote functional vessels in the field. Scale bar¼ 500 mm. (B)
Scanning electron microscopy images of pancreatic blood vessels in PC (LSL-Trp53R172H/+;Pdx-1-Cre) (upper two panels) and KPC (LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx-1-Cre) (lower two panels) mice following treatment with either vehicle or PEGPH20 (n¼4 mice for each cohort) reveal endothelial
fenestrations (white arrowheads) only in PEGPH20-treated KPC mice. (C) Quantification of density of fenestrae in intratumoral KPC blood vessels (n¼3
mice for each cohort, four random vessels per mouse) revealed a significant increase following treatment with PEGPH20 (***p<0.0001). (D)
Representative transmission electron micrographs from vehicle-treated (left panels) and PEGPH20-treated (right panels) tumours (n¼4 mice for each
cohort). Vehicle-treated tumours demonstrate juxtaposed endothelial cell membranes (red arrowheads), while prominent interendothelial gaps are
present following treatment with PEGPH20 (designated by white diamonds, endothelial cell membranes denoted by blue arrowheads).
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GEMM in determining HA’s role in PDA structure and vascular
function.
To determine whether HA could be depleted from primary
pancreatic tumours, PEGPH20 was intravenously administered
to KPC mice and tumours collected over a 3-day time course. A
single dose of PEGPH20 at 4.5 mg/kg depleted intratumoral HA
in a heterogeneous pattern within hours of administration, with
little detectable HA remaining up to 72 h later (figure 1B).
Depletion of HA improves vascular patency and increases
chemotherapeutic delivery
Consistent with previous reports,7 8 less than one-third of the
untreated KPC tumour vasculature is patent as delineated by
Lycopersicon esculentum lectin perfusion (figure 2A). To eval-
uate vascular patency following complete depletion of HA,
KPC mice were treated for 3 days with PEGPH20 prior to
lectin perfusion and were killed. The hyaluronidase regimen
resulted in an increased patency of the tumour vasculature
(70% vs 30%, p¼0.0286, figure 2A). Moreover, the majority of
intratumoral vessels were noted to be prominently open,
and, when measured, the mean vessel luminal area was found
to be significantly increased (p¼0.0085, figure 2B). Since
treatment with PEGPH20 did not affect mean vessel density
(figure S1), we reasoned that any increased perfusion could
be attributed to decompression of existing intratumoral
vessels.
We asked if vascular re-expansion might translate to an
improvement in drug delivery. Exploiting the autofluorescence
of anthracyclines, a significant increase in tumorous doxorubicin
uptake was detected following pretreatment with the hyal-
uronidase (p¼0.026, figure 2C). Similarly, mice receiving
gemcitabine after a single dose of PEGPH20 demonstrated
Figure 3 Continued
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significantly increased intratumoral dFdCTP concentrations
when compared with vehicle-pretreated counterparts
(p¼0.0053, figure 2D). Of note, PEGPH20 did not alter the
plasma pharmacokinetic properties of gemcitabine in control
mice (figure S2).
Depletion of HA increases macromolecular permeability and
induces ultrastructural changes in tumour endothelia
To further characterise the KPC vasculature following HA
depletion, fluorophore-conjugated high-molecular-weight
dextrans (40 kDa and 2 MDa) were infused 30 min prior to
tissue collection.26 Dextran extravasation was minimal in
untreated tumour tissue but increased dramatically following
PEGPH20 treatment (figure 3A). Notably, macromolecular
penetration was not improved in any healthy tissues tested
(figure S3), even among those of high HA content such as cardiac
muscle, suggestive of selective permeabilisation of the tumour
vasculature.
The rapid and extensive intratumoral accumulation of 2 MDa
dextran after PEGPH20 administration was unexpected, given
Figure 4 Combination therapy with
PEGPH20 and gemcitabine inhibits
tumour growth and significantly
extends survival. (A) Tumour volume
measurements from mice treated for
5 days with vehicle (V) (n¼7),
gemcitabine (G) (n¼11), PEGPH20 (P)
(n¼10) and gemcitabine/PEGPH20
combination (P+G) (n¼11)
demonstrate cytostasis only in
response to gemcitabine/PEGPH20
combination therapy. (B) Proliferation of
pancreatic tumour cells in response to
PEGPH20 treatment. A significant
decrease in pancreatic tumour cell
proliferation is observed 5 days after
treatment with PEGPH20 and
gemcitabine compared with
gemcitabine alone. ManneWhitney U
test, *p¼0.0432. (C) KaplaneMeier
survival curve for vehicle-treated (n¼8,
grey dotted line), gemcitabine-treated
(n¼15, black dotted line), PEGPH20-
treated (n¼12, green line) and
gemcitabine/PEGPH20-treated (n¼10,
red line) KPC cohorts. A significant
increase in survival was observed in
gemcitabine/PEGPH20-treated mice
relative to the gemcitabine-treated
cohort. Log-rank ***p¼0.0002, HR
0.06794. PH3, phospho-histone H3.
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its large Stoke’s radius. This prompted an examination of the
tumour endothelial ultrastructure for vascular integrity and
markers of induced hyperpermeability, which include fenestrae
and intercellular gaps.27e29 Notably, scanning electron micros-
copy revealed few fenestrations in the untreated tumour,
comparable to endothelia in the healthy pancreata of control
mice (figure 3B). Moreover, treatment-naive vasculature showed
intact interendothelial junctions by transmission electron micros-
copy (figure 3D). By contrast, PEGPH20 induced a significant
increase in fenestrae (p<0.0001, figure 3B,C) and more prominent
interendothelial gaps (figure 3D), a hyperpermeability-associated
phenotype reminiscent of VEGF-activated vasculature.27e29
Combination therapy with PEGPH20 and gemcitabine inhibits
tumour growth and significantly extends survival
Given the improvement in pharmacodelivery, we evaluated
whether PEGPH20 provided any therapeutic benefit to KPC
mice either alone or in combination with gemcitabine. While
gemcitabine monotherapy decreased tumour growth only
modestly, the combination of PEGPH20 and gemcitabine
significantly inhibited growth over 5 days of treatment
(p<0.001, figure 4A). During the same period, PEGPH20
monotherapy had no effect on tumour growth (figure 4A).
Growth inhibition was accompanied by a decrease in intra-
tumoral proliferation as assessed by phospho-histone H3
staining (p¼0.043, figure 4B).
To determine whether these findings impacted upon the
lethality of PDA, KPC mice were subsequently treated for an
extended period with each agent as monotherapy, with a vehicle
or with the gemcitabine/PEGPH20 combination. Similar to the
5-day analysis, treatment with PEGPH20 or gemcitabine alone
had insignificant effects on the survival of KPC mice in
comparison to vehicle-treated mice (figure 4C). However,
extended treatment with the gemcitabine/PEGPH20 combina-
tion significantly improved median survival over gemcitabine
monotherapy (28.5 vs 15 days, p¼0.002, figure 4C). Most mice
in the gemcitabine/PEGPH20 combination cohort experienced
stable tumour growth (figure S4) and hyaluronidase activity
persisted up to study end point (figure S5).
DISCUSSION
We recently proposed that microenvironmental impairment in
drug delivery may contribute towards the intrinsic chemo-
resistance of pancreatic cancer and used the Smoothened
inhibitor IPI-926 to augment the response to gemcitabine in
KPC mice.7 However, since hedgehog signalling is implicated in
the survival and propagation of stem-like cancer cells and
cancer-associated fibroblasts,30e32 an additional antitumour
effect by IPI-926 could not be excluded. The current study with
PEGPH20 supports the hypothesis that improvement of phar-
macodelivery through depletion of select stromal components
may be sufficient for the therapeutic response previously
reported.7
The scarcity of endothelial fenestrations and open inter-
endothelial junctions in treatment-naive KPC tumours stands in
contrast to observations in xenografts, allografts and some
spontaneous tumour models. A defective endothelial monolayer,
characterised by abundant diaphragmed fenestrae and intercel-
lular openings, is associated with VEGF-induced hyper-
permeability27 28 and underlies the vascular leakiness seen in
these models.29 33 Since these ultrastructural changes may
permit access to therapeutic agents,29 their absence may
contribute towards delivery inefficiency in the KPC tumour and
explain the differential chemotherapeutic sensitivities between
spontaneous tumours and other models.7 Moreover, the obser-
vation points to relative inactivity of VEGF in the tumour and is
suggestive of signalling antagonism from the abundant angio-
static factors in KPC stroma.34 Such an antiangiogenic milieu is
generated by complex tumourefibroblast interactions in PDA35
and is frequently absent or lost in the pathogenesis of other
tumour models.36 Furthermore, the persistence of negative
regulators of angiogenesis would explain the hypovascular
phenotype and the failure of anti-VEGF agents in human PDA
and its GEMMs.8 37e39
The unanticipated induction of fenestrae and impairment of
junctional integrity following PEGPH20 may reflect the role of
HA signalling in maintaining the PDA intratumoral vascular
endothelium in a quiescent state. HA has been shown to impart
increased barrier integrity and resistance to lipopolysaccharide-
induced hyperpermeability through CD44-dependent reorgan-
isation of the endothelial actin cytoskeleton.40 Consistent with
this finding, disruption of the HAeCD44 interaction in vivo by
systemic administration of an anti-CD44 monoclonal results in
a rapid permeability increase.41 The generation of low-molec-
ular-weight HA fragments (including oligosaccharides) in large
quantities from intratumoral HA could antagonise existing
HAeCD44 interactions15 42 and may explain for the tumour
specificity of PEGPH20-induced hyperpermeability.
The ultrastructural changes and the vascular re-expansion
from IFP reduction have a multiplicative effect on intra-
tumoral diffusion and convection by increasing both compo-
nents of the permeability-surface area product.43 Furthermore,
IFP reduction results in a favourable hydrostatic pressure
gradient for convective solute delivery. The specificity of this
effect to the tumour suggests utility as an adjunct to agents of
larger hydrodynamic size, such as polymeric drugs, mono-
clonal antibodies and albumin conjugates. Nonetheless, as
prior work in xenografts suggested monotherapy activity of
PEGPH20,20 we cannot exclude the possibility that HA
depletion also sensitises neoplastic cells to gemcitabine
toxicity by removing various survival cues. Finally, the
synergism of PEGPH20 and gemcitabine demonstrated in this
study is of immediate clinical significance and provides
support for investigational trials with this therapeutic
combination (NCT01453153).
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